Table 2 Clinical trial and patient characteristics
N = 2896 | Percentage (%) | |
|---|---|---|
Clinical trial characteristic | ||
Enrollment year | ||
1988–1991 | 591 | 20.4 |
1992–2001 | 1057 | 36.5 |
2002–2011 | 1248 | 43.1 |
Novel agenta utilized | ||
Yes | 1087 | 37.5 |
No | 1809 | 62.5 |
Stem cell transplant utilized | ||
Yes | 918 | 31.7 |
No | 1978 | 68.3 |
Duration of treatment | ||
Fixed duration | 607 | 21.0 |
Treatment to progression | 2289 | 79.0 |
Patient characteristic | ||
Race-ethnicity | ||
Non-Hispanic White | 2373 | 81.9 |
Non-Hispanic African Americans | 392 | 13.5 |
Non-Hispanic other | 55 | 1.9 |
Hispanic | 76 | 2.6 |
Age | ||
<70 years | 2195 | 75.8 |
≥70 years | 701 | 24.2 |
Gender | ||
Male | 1693 | 58.5 |
Female | 1203 | 41.5 |
International Staging System | ||
ISS I–II | 1733 | 71.4 |
ISS III | 694 | 28.6 |
Missing | 469 | |
ECOG performance status | ||
PS = 0 | 1006 | 35.0 |
PS > 0 | 1869 | 65.0 |
Missing | 21 | |
Hemoglobin | ||
Hb > 10 g/dL | 1750 | 60.6 |
Hb ≤ 10 g/dL | 1136 | 39.4 |
Missing | 10 | |
Lytic lesions | ||
LL absent | 1040 | 36.1 |
LL present | 1838 | 63.9 |
Missing | 18 | |
Calcium | ||
Ca ≤ 12 mg/dL | 2759 | 96.2 |
Ca > 12 mg/dL | 109 | 3.8 |
Missing | 28 | |
Creatinine | ||
Cr < 2 mg/dL | 2238 | 86.8 |
Cr ≥ 2 mg/dL | 340 | 13.2 |
Missing | 318 | |
